Edward B Garon

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
    Edward B Garon
    1Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 9:1985-94. 2010
  2. doi request reprint Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
    Edward B Garon
    Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA Electronic address
    Semin Oncol 42:S11-8. 2015
  3. doi request reprint Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    Edward B Garon
    David Geffen School of Medicine at UCLA Translational Research in Oncology US Network, Los Angeles, CA, USA Electronic address
    Lancet 384:665-73. 2014
  4. pmc Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
    Edward B Garon
    Division of Hematology Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Cancer Res Clin Oncol 140:443-52. 2014
  5. pmc The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
    Edward B Garon
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 12:890-900. 2013
  6. pmc Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
    Edward B Garon
    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90404, USA
    J Thorac Oncol 8:270-8. 2013
  7. doi request reprint A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an
    Edward B Garon
    Translational Oncology Research International Network, University of California Los Angeles, Los Angeles, CA, USA
    Clin Lung Cancer 13:505-9. 2012
  8. pmc Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer
    Edward B Garon
    David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    Lung Cancer 77:475-81. 2012
  9. pmc High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation
    Cindy Mong
    Division of Hematology Oncology, UCLA David Geffen School of Medicine, 200 UCLA Medical Plaza, Suite 420 Los Angeles, CA 90024 USA
    J Cardiothorac Surg 6:19. 2011
  10. ncbi request reprint In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies
    Edward B Garon
    Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int J Cancer 121:675-82. 2007

Detail Information

Publications19

  1. pmc Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
    Edward B Garon
    1Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 9:1985-94. 2010
    ..In total, these results suggest that clinical trials of selumetinib in breast cancer and NSCLC might select patients whose tumors harbor raf and ras mutations, respectively...
  2. doi request reprint Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
    Edward B Garon
    Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA Electronic address
    Semin Oncol 42:S11-8. 2015
    ..PD-L1 expression as a potential biomarker to select patients most likely to respond to inhibitors of the PD-1 pathway has been widely studied. ..
  3. doi request reprint Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    Edward B Garon
    David Geffen School of Medicine at UCLA Translational Research in Oncology US Network, Los Angeles, CA, USA Electronic address
    Lancet 384:665-73. 2014
    ..We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy...
  4. pmc Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
    Edward B Garon
    Division of Hematology Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Cancer Res Clin Oncol 140:443-52. 2014
    ..We designed this open-label phase II trial to determine the response rate, safety, and tolerability of oral DCA in patients with metastatic breast cancer and advanced stage non-small cell lung cancer (NSCLC)...
  5. pmc The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
    Edward B Garon
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 12:890-900. 2013
    ..These data will help inform the evaluation of correlative data from a recently completed phase II NSCLC trial and a planned phase IB trial of NVP-AUY922 in combination with pemetrexed in NSCLCs...
  6. pmc Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
    Edward B Garon
    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90404, USA
    J Thorac Oncol 8:270-8. 2013
    ..To explore cross-communication between ER and EGFR, we have correlated ER pathway gene and protein expression profiles and examined effects of antiestrogens with or without EGFR inhibitors in preclinical models of human NSCLC...
  7. doi request reprint A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an
    Edward B Garon
    Translational Oncology Research International Network, University of California Los Angeles, Los Angeles, CA, USA
    Clin Lung Cancer 13:505-9. 2012
    ....
  8. pmc Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer
    Edward B Garon
    David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    Lung Cancer 77:475-81. 2012
    ..With a series of recent advances toward increasingly personalized biomarker-directed anticancer therapies, the appropriateness of the traditional regulatory approach has been questioned...
  9. pmc High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation
    Cindy Mong
    Division of Hematology Oncology, UCLA David Geffen School of Medicine, 200 UCLA Medical Plaza, Suite 420 Los Angeles, CA 90024 USA
    J Cardiothorac Surg 6:19. 2011
    ..This study was designed to assess the prevalence of smoking at time of lung cancer diagnosis in a surgical patient cohort referred for cardiothoracic surgery...
  10. ncbi request reprint In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies
    Edward B Garon
    Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int J Cancer 121:675-82. 2007
    ..Therefore, nanoelectropulse therapy deserves further study as a potentially effective cancer therapy...
  11. ncbi request reprint Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells
    Edward B Garon
    Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA 90095 7059, USA
    Leuk Res 31:643-51. 2007
    ..These results establish QDs as extremely useful molecular imaging tools for the study of hematologic cells...
  12. pmc Development of transcriptomic biomarker signature in human saliva to detect lung cancer
    Lei Zhang
    School of Dentistry and Dental Research Institute, University of California, Los Angeles, 90095, USA
    Cell Mol Life Sci 69:3341-50. 2012
    ..These results poised the salivary biomarkers for the initiation of a multi-center validation in a definitive clinical context...
  13. pmc (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
    Matthias R Benz
    Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 7371, USA
    J Nucl Med 52:1684-9. 2011
    ..Here we determined whether early changes in tumor uptake of (18)F-FDG can predict progression-free and overall survival in NSCLC patients who are treated with erlotinib...
  14. doi request reprint Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer
    Nalo Hamilton
    UCLA School of Nursing, Los Angeles, CA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
    Crit Rev Oncog 20:373-90. 2015
    ..Further, the potential benefit of metformin treatment in patients with TNBC as well as areas of therapeutic potential in the IGF-ERβ1 pathway are highlighted. ..
  15. pmc The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer
    Nadiyah Kazmi
    UCLA Geffen School of Medicine, Department of Medicine, Division of Hematology Oncology, Factor Building 11 934, 700 Tiverton Avenue, Los Angeles, CA 90095 16781, USA
    Lung Cancer Manag 1:259-272. 2012
    ..Results will help guide future lung cancer management decisions, with a goal of achieving more effective and less toxic treatments for patients...
  16. pmc Uncertainty and psychological adjustment in patients with lung cancer
    Keiko Kurita
    Department of Psychology, University of Southern California, Los Angeles, CA 90089 1061, USA
    Psychooncology 22:1396-401. 2013
    ....
  17. pmc A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
    Edward B Garon
    Department of Medicine Department of Hematology and Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
    Onco Targets Ther 9:7275-7283. 2016
    ..This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-naïve subjects with advanced nonsquamous, non-small-cell lung cancer...
  18. pmc Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer
    Kostyantyn Krysan
    Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA Los Angeles, CA
    Am J Transl Res 5:481-96. 2013
    ..Correlations between plasma neutrophil gelatinase associated lipocalin (NGAL) levels, erlotinib response and the EGFR mutational status were assessed in advanced stage NSCLC patients treated with erlotinib...
  19. pmc Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry
    Hua Xiao
    Dental Research Institute, University of California, Los Angeles, Los Angeles, California 90095, USA
    Mol Cell Proteomics 11:M111.012112. 2012
    ..The discriminatory power of these candidate biomarkers indicate that a simple saliva test might be established for lung cancer clinical screening and detection...